Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Funding for Neurodegenerative Disease

Published: Friday, July 26, 2013
Last Updated: Friday, July 26, 2013
Bookmark and Share
The Centres of Excellence in neurodegenerative disease (CoEN) initiative funds collaborative research in the field of neurodegenerative disease.

Under the second CoEN funding call, £2.6m has been awarded for 5 “Pathfinder” projects, constituting innovative and creative proof of principle studies which, if successful, will provide a step change in neurodegeneration research.

The awarded projects take a ‘high risk, high pay-off’ approach to identify and validate new potential drugs and develop innovative therapeutic approaches for Parkinson’s Disease, Alzheimer’s Disease and other dementias. These projects bring together a wealth of resources and expertise from a number of research centres in different countries to tackle scientific questions that are vital to advancement within the field.

To ensure momentum, successful “pathfinders” will have the potential, in subsequent phases of the initiative, to win substantial follow-on funding that will help take the proof of principle studies to the next stage where they can have wider scientific and clinical impact.
The funded projects are:

•    Targeting glucocerebrosidase for disease-modifying treatments in Parkinson’s disease
•    Anthony H.V. Schapira (UK), David Park (Canada), Donato Di Monte (Germany) and Fabio Blandini (Italy)
•    WNT signaling: biomarker and target evaluation in Alzheimer’s disease
•    Antonio Cuadrado (Spain), James Woodgett (Canada) and Simon Lovestone (UK)
•    Mechanisms of amyloid-β clearance in models of vascular cognitive impairment and mixed dementia
•    Gabor Petzold (Germany) and Danica Stanimirovic (Canada)
•    In vivo neuronal cell reprogramming for a new regenerative approach in Parkinson’s disease
•    Vania Broccoli (Italy), Alexander Dityatev (Germany) and Josè Luis Lanciego (Spain)
•    microRNA as novel therapeutic targets and disease biomarkers in Alzheimer's Disease, Frontotemporal dementia and Amyotrophic lateral sclerosis (NEURO-MIR)
•    Jochen Prehn (Ireland), Andre Fischer (Germany), Pierre Lau (Flanders), Jose Lucas (Spain)

CoEN is an international initiative involving research funders in the UK (Medical Research Council), Canada (Canadian Institutes of Health Research), Germany (DZNE), Belgium (Flanders, VIB), Ireland (Science Foundation Ireland and Heath Research Board Ireland), Italy (Ministry of Health), Slovakia (Slovak Ministry of Education, Science, Research and Sport), and Spain (ISCIII). The aim of the initiative is to encourage collaborative research between recognised national centres of excellence in neurodegeneration research.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First RNAi Meiosis Screen Reveals Genes Essential to Generate Eggs
Screening techniques developed leading to the discovery of genes essential for meiosis in mammals.
Wednesday, July 08, 2015
£93 Million Package of Support Announced for UK’s Health Industries
Innovative business and academic projects will benefit from a new £93.2 million package of support.
Wednesday, July 31, 2013
Scientists uncover new hereditary links to Alzheimer’s disease
Two genes which increase a person’s likelihood of developing the most common form of Alzheimer’s disease have been discovered in the largest-ever study of its kind into the illness.
Monday, October 05, 2009
Location of genetic varation is key to potential role in disease
Genetic variation is widely recognised as the key to survival and continued evolution of a species.
Friday, August 22, 2008
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos